The value of using polymorphisms in anti-platelet therapy

Haybar, Habib; Zayeri, Zeinab Deris

doi:10.1007/s11515-017-1456-0

Cited by 5 publications

(2 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, Clopidogrel is one of the most common antiplatelet drugs used for the prevention of ischemic vascular atherosclerotic disease, acute coronary syndrome (ACS), as well as prevention of Stent thrombosis (3)(4)(5). Despite the benefits of using the clopidogrel, some patients experience recurrent ischemic events (6). Platelet reactivity assays showed inter-individual variability in the biological response to clopidogrel (7).…”

Section: Introductionmentioning

confidence: 99%

Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran

Haybar

Ghadiri

Ghandil

et al. 2020

Jundishapur J Chronic Dis Care

Self Cite

View full text Add to dashboard Cite

Background: Clopidogrel is a platelet inhibitor drug widely used in patients undergoing percutaneous coronary intervention (PCI) for the prevention of stent thrombosis. Genetic variation within CYP2C19 gene causes variable clopidogrel response. The FDA has recommended CYP2C19 genotyping in the patients taking clopidogrel, especially in the population with high prevalence rates of CYP2C19 *2 and *3 alleles. Objectives: The aim of this study was to determine the prevalence of CYP2C19 gene polymorphisms in the population received Drug-Eluting Stents following PCI in the southwest of Iran. Methods: This cross-sectional study was conducted on 102 patients undergoing PCI. Demographic characteristics and risk factors of patients were collected using a questionnaire and CYP2C19 genotyping was carried out by PCR-RFLP. Then CYP2C19 allele and genotype frequencies were determined and analyzed using χ 2 test.

show abstract

Section: Introductionmentioning

confidence: 99%

Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran

Haybar

Ghadiri

Ghandil

et al. 2020

Jundishapur J Chronic Dis Care

Self Cite

View full text Add to dashboard Cite

show abstract

“…Atherosclerotic plaques are the main features of atherosclerosis that progressively narrow the coronary artery lumen and hence disrupt myocardial blood flow. Based on the severity of obstruction and the rate of development, it may also cause myocardial infarction (MI) (2). The incidence of CAD has increased due to increased obesity and other CVD risk factors.…”

Section: Introductionmentioning

confidence: 99%

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

Seyedian

Soltani

Saki

et al. 2020

Jundishapur J Chronic Dis Care

Self Cite

View full text Add to dashboard Cite

Background: Coronary artery disease (CAD) is one of the main causes of mortality in the world. The role of Von Willebrand Factor (VWF) is very important in platelet adhesion, microcirculation, and acute stenosis and it contributes to the development of atherothrombotic processes. Objectives: We decided to evaluate the level of VWF in diabetic and non-diabetic patients as an effective factor in CAD. Methods: This study was performed on 65 patients (32 diabetic patients and 33 non-diabetic patients), who referred to an Echocardiography and Angiography Department. They were evaluated for the VWF level, blood group, and fasting blood glucose. Patients underwent echocardiography, angiography, and, if necessary, percutaneous coronary intervention (PCI) during the hospitalization. They also underwent coronary artery bypass grafting (CABG) if they needed the surgery. After 40 days, we evaluated the anterior STelevation myocardial infarction (STEMI), mortality, major adverse cardiac events (MACE), heart failure, and limb ischemia. Results: The VWF level was significantly higher in diabetic patients (P < 0.0001). Also, the increased VWF levels were significantly more frequent in diabetic patients under CABG than in non-diabetic patients under CABG (P = 0.013). There was a significant relationship between positive MACE and increased VWF levels. Conclusions: The level of VWF in diabetic patients increases cardiovascular problems. Therefore, it seems that these patients can benefit from VWF-reducing drugs. Clinical research can be promising in this field.

show abstract

The comparison of insulin and uric acid levels in adolescents with and without metabolic syndrome

et al. 2018

View full text Add to dashboard Cite

The value of using polymorphisms in anti-platelet therapy

Cited by 5 publications

References 59 publications

Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran

Allele and Genotype Frequencies of CYP2C19 in Patients with Drug-Eluting Stents Following Percutaneous Coronary Intervention in Southwest of Iran

Effect of Von Willebrand Antigen on Mortality and Major Adverse Cardiac Events in Diabetic and Non-diabetic Patients with Anterior ST Elevated Myocardial Infarction

The comparison of insulin and uric acid levels in adolescents with and without metabolic syndrome

Contact Info

Product

Resources

About